Predictors of inhaled corticosteroid taper failure in adults with asthma

National Heart, Lung, and Blood Institute Asthmanet

doi:10.1016/j.jaip.2018.05.039

Predictors of inhaled corticosteroid taper failure in adults with asthma

National Heart, Lung, and Blood Institute Asthmanet

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	1335-1337.e3
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	7
Issue number	4
DOIs	https://doi.org/10.1016/j.jaip.2018.05.039
State	Published - Apr 2019

All Science Journal Classification (ASJC) codes

Immunology and Allergy

Access to Document

10.1016/j.jaip.2018.05.039

Cite this

@article{0cb9018c1bec4037a0d1f12ab39f535f,

title = "Predictors of inhaled corticosteroid taper failure in adults with asthma",

author = "{National Heart, Lung, and Blood Institute Asthmanet} and Cardet, {Juan Carlos} and Codispoti, {Christopher D.} and Tonya King and Leonard Bacharier and Tara Carr and Mario Castro and Vernon Chinchilli and Ryan Dunn and Fernando Holquing and Linda Engle and Kyle Nelson and Ortega, {Victor E.} and Michael Peters and Sima Ramratnam and Krishnan, {Jerry A.} and Wechsler, {Michael E.} and Elliot Israel",

note = "Funding Information: This study was supported by the National Heart, Lung, and Blood Institute (grant nos. HL098102 , U10HL098096 , UL1TR000150 , UL1TR000430 , UL1TR000050 , HL098075 , UL1TR001082 , HL098090 , HL098177 , UL1TR000439 , HL098098 , UL1TR000448 , HL098107 , HL098112 , HL098103 , UL1TR000454 , and HL098115 ). Funding Information: This study was supported by the National Heart, Lung, and Blood Institute (grant nos. HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and HL098115).Conflicts of interest: J. C. Cardet reports grant support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (K23AI125785) during the conduct of the study. T. S. King reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. L. Bacharier reports grants from the National Institutes of Health (NIH)/NHLBI during the conduct of the study and personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Vectura, and Circassia, outside the submitted work. T. Carr reports grants from NIH-NHLBI AsthmaNet during the conduct of the study and personal fees from AstraZeneca and Regeneron, outside the submitted work. M. Castro reports grants from the NIH and the American Lung Association during the conduct of the study; personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GSK, Holaira, and Teva; and grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, MedImmune, Sanofi-Aventis, and Vectura, all outside the submitted work. V. Chinchilli reports grants from the NHLBI during the conduct of the study. L. Engle reports grants from the NIH-NHLBI during the conduct of the study. M. Peters reports personal fees from Merck and Genentech, outside the submitted work. J. A. Krishnan reports grants from the Patient-Centered Outcomes Research Institute and the NIH, outside the submitted work. M. E. Wechsler reports personal fees from AstraZeneca, Vectura, Regeneron, Meda, Mylan, Gilacure, Tunitas, Genentech, Theravance, Neurotronic, Sentien, Teva, Boehringer Ingelheim, BSCI, and Novartis and grants and personal fees from Sanofi and GlaxoSmithKline, outside the submitted work. E. Israel reports personal fees from AstraZeneca, Pneuma Respiratory, Sanofi, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Philips Respironics, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Inc, and Regeneron Pharmaceuticals; personal fees and other fees from Novartis and Teva Specialty Pharmaceuticals; other fees from Research in Real Life and Vorso Corp.; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, Teva, and Teva Specialty Pharmaceuticals, outside the submitted work. This study was supported by the National Heart, Lung, and Blood Institute (grant nos. HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and HL098115). Conflicts of interest: J. C. Cardet reports grant support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (K23AI125785) during the conduct of the study. T. S. King reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. L. Bacharier reports grants from the National Institutes of Health (NIH)/NHLBI during the conduct of the study and personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Vectura, and Circassia, outside the submitted work. T. Carr reports grants from NIH-NHLBI AsthmaNet during the conduct of the study and personal fees from AstraZeneca and Regeneron, outside the submitted work. M. Castro reports grants from the NIH and the American Lung Association during the conduct of the study; personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GSK, Holaira, and Teva; and grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, MedImmune, Sanofi-Aventis, and Vectura, all outside the submitted work. V. Chinchilli reports grants from the NHLBI during the conduct of the study. L. Engle reports grants from the NIH-NHLBI during the conduct of the study. M. Peters reports personal fees from Merck and Genentech, outside the submitted work. J. A. Krishnan reports grants from the Patient-Centered Outcomes Research Institute and the NIH, outside the submitted work. M. E. Wechsler reports personal fees from AstraZeneca, Vectura, Regeneron, Meda, Mylan, Gilacure, Tunitas, Genentech, Theravance, Neurotronic, Sentien, Teva, Boehringer Ingelheim, BSCI, and Novartis and grants and personal fees from Sanofi and GlaxoSmithKline, outside the submitted work. E. Israel reports personal fees from AstraZeneca, Pneuma Respiratory, Sanofi, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Philips Respironics, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Inc, and Regeneron Pharmaceuticals; personal fees and other fees from Novartis and Teva Specialty Pharmaceuticals; other fees from Research in Real Life and Vorso Corp.; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, Teva, and Teva Specialty Pharmaceuticals, outside the submitted work. Funding Information: Conflicts of interest: J. C. Cardet reports grant support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (K23AI125785) during the conduct of the study. T. S. King reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. L. Bacharier reports grants from the National Institutes of Health (NIH)/NHLBI during the conduct of the study and personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Vectura, and Circassia, outside the submitted work. T. Carr reports grants from NIH-NHLBI AsthmaNet during the conduct of the study and personal fees from AstraZeneca and Regeneron, outside the submitted work. M. Castro reports grants from the NIH and the American Lung Association during the conduct of the study; personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GSK, Holaira, and Teva; and grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, MedImmune, Sanofi-Aventis, and Vectura, all outside the submitted work. V. Chinchilli reports grants from the NHLBI during the conduct of the study. L. Engle reports grants from the NIH-NHLBI during the conduct of the study. M. Peters reports personal fees from Merck and Genentech, outside the submitted work. J. A. Krishnan reports grants from the Patient-Centered Outcomes Research Institute and the NIH, outside the submitted work. M. E. Wechsler reports personal fees from AstraZeneca, Vectura, Regeneron, Meda, Mylan, Gilacure, Tunitas, Genentech, Theravance, Neurotronic, Sentien, Teva, Boehringer Ingelheim, BSCI, and Novartis and grants and personal fees from Sanofi and GlaxoSmithKline, outside the submitted work. E. Israel reports personal fees from AstraZeneca, Pneuma Respiratory, Sanofi, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Philips Respironics, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Inc, and Regeneron Pharmaceuticals; personal fees and other fees from Novartis and Teva Specialty Pharmaceuticals; other fees from Research in Real Life and Vorso Corp.; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, Teva, and Teva Specialty Pharmaceuticals, outside the submitted work.",

year = "2019",

month = apr,

doi = "10.1016/j.jaip.2018.05.039",

language = "English (US)",

volume = "7",

pages = "1335--1337.e3",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "American Academy of Allergy, Asthma and Immunology",

number = "4",

}

TY - JOUR

T1 - Predictors of inhaled corticosteroid taper failure in adults with asthma

AU - National Heart, Lung, and Blood Institute Asthmanet

AU - Cardet, Juan Carlos

AU - Codispoti, Christopher D.

AU - King, Tonya

AU - Bacharier, Leonard

AU - Carr, Tara

AU - Castro, Mario

AU - Chinchilli, Vernon

AU - Dunn, Ryan

AU - Holquing, Fernando

AU - Engle, Linda

AU - Nelson, Kyle

AU - Ortega, Victor E.

AU - Peters, Michael

AU - Ramratnam, Sima

AU - Krishnan, Jerry A.

AU - Wechsler, Michael E.

AU - Israel, Elliot

N1 - Funding Information: This study was supported by the National Heart, Lung, and Blood Institute (grant nos. HL098102 , U10HL098096 , UL1TR000150 , UL1TR000430 , UL1TR000050 , HL098075 , UL1TR001082 , HL098090 , HL098177 , UL1TR000439 , HL098098 , UL1TR000448 , HL098107 , HL098112 , HL098103 , UL1TR000454 , and HL098115 ). Funding Information: This study was supported by the National Heart, Lung, and Blood Institute (grant nos. HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and HL098115).Conflicts of interest: J. C. Cardet reports grant support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (K23AI125785) during the conduct of the study. T. S. King reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. L. Bacharier reports grants from the National Institutes of Health (NIH)/NHLBI during the conduct of the study and personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Vectura, and Circassia, outside the submitted work. T. Carr reports grants from NIH-NHLBI AsthmaNet during the conduct of the study and personal fees from AstraZeneca and Regeneron, outside the submitted work. M. Castro reports grants from the NIH and the American Lung Association during the conduct of the study; personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GSK, Holaira, and Teva; and grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, MedImmune, Sanofi-Aventis, and Vectura, all outside the submitted work. V. Chinchilli reports grants from the NHLBI during the conduct of the study. L. Engle reports grants from the NIH-NHLBI during the conduct of the study. M. Peters reports personal fees from Merck and Genentech, outside the submitted work. J. A. Krishnan reports grants from the Patient-Centered Outcomes Research Institute and the NIH, outside the submitted work. M. E. Wechsler reports personal fees from AstraZeneca, Vectura, Regeneron, Meda, Mylan, Gilacure, Tunitas, Genentech, Theravance, Neurotronic, Sentien, Teva, Boehringer Ingelheim, BSCI, and Novartis and grants and personal fees from Sanofi and GlaxoSmithKline, outside the submitted work. E. Israel reports personal fees from AstraZeneca, Pneuma Respiratory, Sanofi, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Philips Respironics, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Inc, and Regeneron Pharmaceuticals; personal fees and other fees from Novartis and Teva Specialty Pharmaceuticals; other fees from Research in Real Life and Vorso Corp.; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, Teva, and Teva Specialty Pharmaceuticals, outside the submitted work. This study was supported by the National Heart, Lung, and Blood Institute (grant nos. HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and HL098115). Conflicts of interest: J. C. Cardet reports grant support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (K23AI125785) during the conduct of the study. T. S. King reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. L. Bacharier reports grants from the National Institutes of Health (NIH)/NHLBI during the conduct of the study and personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Vectura, and Circassia, outside the submitted work. T. Carr reports grants from NIH-NHLBI AsthmaNet during the conduct of the study and personal fees from AstraZeneca and Regeneron, outside the submitted work. M. Castro reports grants from the NIH and the American Lung Association during the conduct of the study; personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GSK, Holaira, and Teva; and grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, MedImmune, Sanofi-Aventis, and Vectura, all outside the submitted work. V. Chinchilli reports grants from the NHLBI during the conduct of the study. L. Engle reports grants from the NIH-NHLBI during the conduct of the study. M. Peters reports personal fees from Merck and Genentech, outside the submitted work. J. A. Krishnan reports grants from the Patient-Centered Outcomes Research Institute and the NIH, outside the submitted work. M. E. Wechsler reports personal fees from AstraZeneca, Vectura, Regeneron, Meda, Mylan, Gilacure, Tunitas, Genentech, Theravance, Neurotronic, Sentien, Teva, Boehringer Ingelheim, BSCI, and Novartis and grants and personal fees from Sanofi and GlaxoSmithKline, outside the submitted work. E. Israel reports personal fees from AstraZeneca, Pneuma Respiratory, Sanofi, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Philips Respironics, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Inc, and Regeneron Pharmaceuticals; personal fees and other fees from Novartis and Teva Specialty Pharmaceuticals; other fees from Research in Real Life and Vorso Corp.; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, Teva, and Teva Specialty Pharmaceuticals, outside the submitted work. Funding Information: Conflicts of interest: J. C. Cardet reports grant support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (K23AI125785) during the conduct of the study. T. S. King reports grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. L. Bacharier reports grants from the National Institutes of Health (NIH)/NHLBI during the conduct of the study and personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Vectura, and Circassia, outside the submitted work. T. Carr reports grants from NIH-NHLBI AsthmaNet during the conduct of the study and personal fees from AstraZeneca and Regeneron, outside the submitted work. M. Castro reports grants from the NIH and the American Lung Association during the conduct of the study; personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GSK, Holaira, and Teva; and grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, MedImmune, Sanofi-Aventis, and Vectura, all outside the submitted work. V. Chinchilli reports grants from the NHLBI during the conduct of the study. L. Engle reports grants from the NIH-NHLBI during the conduct of the study. M. Peters reports personal fees from Merck and Genentech, outside the submitted work. J. A. Krishnan reports grants from the Patient-Centered Outcomes Research Institute and the NIH, outside the submitted work. M. E. Wechsler reports personal fees from AstraZeneca, Vectura, Regeneron, Meda, Mylan, Gilacure, Tunitas, Genentech, Theravance, Neurotronic, Sentien, Teva, Boehringer Ingelheim, BSCI, and Novartis and grants and personal fees from Sanofi and GlaxoSmithKline, outside the submitted work. E. Israel reports personal fees from AstraZeneca, Pneuma Respiratory, Sanofi, Merck, Entrinsic Health Solutions, GlaxoSmithKline, Philips Respironics, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Inc, and Regeneron Pharmaceuticals; personal fees and other fees from Novartis and Teva Specialty Pharmaceuticals; other fees from Research in Real Life and Vorso Corp.; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, Teva, and Teva Specialty Pharmaceuticals, outside the submitted work.

PY - 2019/4

Y1 - 2019/4

UR - http://www.scopus.com/inward/record.url?scp=85054093362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054093362&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2018.05.039

DO - 10.1016/j.jaip.2018.05.039

M3 - Article

C2 - 30240889

AN - SCOPUS:85054093362

SN - 2213-2198

VL - 7

SP - 1335-1337.e3

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 4

ER -

Predictors of inhaled corticosteroid taper failure in adults with asthma

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this